Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph I Safety, Tolerability & PK of Intravenously Administered MIK665 in Pts w/ r/r Lymphoma or MM

Protocol: OSU-17081

Full Title

Phase I Open Label, Multi-Center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, A Mcl-1 Inhibitor, In Patients with Refractory or Relapsed Lymphoma or Multiple Myeloma

Multiple Myeloma Lymphoma Non-Hodgkin’s Lymphoma (B- & T-Cell)